Kronos Bio, Inc.
General ticker "KRON" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $58.7M (TTM average)
Kronos Bio, Inc. does not follow the US Stock Market performance with the rate: -5.6%.
Estimated limits based on current volatility of 1.9%: low 0.87$, high 0.90$
Factors to consider:
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.87$, 2.69$]
- 2025-12-31 to 2026-12-31 estimated range: [0.96$, 2.80$]
Financial Metrics affecting the KRON estimates:
- Negative: Non-GAAP EPS, $ of -1.43 <= 0.04
- Negative: negative Net income
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -52.96 <= 1.76
- Negative: Shareholder equity ratio, % of 70.42 > 63.76
Short-term KRON quotes
Long-term KRON plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $6.29MM | $9.85MM |
| Operating Expenses | $137.12MM | $128.37MM | $102.73MM |
| Operating Income | $-137.12MM | $-122.08MM | $-92.89MM |
| Non-Operating Income | $3.91MM | $9.40MM | $6.81MM |
| R&D Expense | $93.72MM | $84.52MM | $48.66MM |
| Income(Loss) | $-133.20MM | $-112.67MM | $-86.08MM |
| Profit(Loss)* | $-129.29MM | $-112.67MM | $-86.08MM |
| Stockholders Equity | $244.50MM | $159.08MM | $87.58MM |
| Inventory | $10.33MM | $0.00MM | $0.00MM |
| Assets | $294.94MM | $213.28MM | $124.36MM |
| Operating Cash Flow | $-90.93MM | $-78.58MM | $-65.44MM |
| Capital expenditure | $0.58MM | $0.68MM | $0.00MM |
| Investing Cash Flow | $-32.22MM | $66.37MM | $85.44MM |
| Financing Cash Flow | $0.85MM | $0.57MM | $0.24MM |
| Earnings Per Share** | $-2.30 | $-1.95 | $-1.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.